Elucidation of Novel Molecular Targets for Therapeutic Strategies in Urothelial Carcinoma: A Literature Review
| Autor: | Bagi Jana, Angelina Hong, Blessie Nelson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research Metastatic Urothelial Carcinoma FDA approvals molecular targets Angiogenesis medicine.medical_treatment Review Targeted therapy Cell therapy 03 medical and health sciences 0302 clinical medicine medicine RC254-282 urothelial carcinoma PI3K/AKT/mTOR pathway clinical trials Chemotherapy Bladder cancer business.industry Neoplasms. Tumors. Oncology. Including cancer and carcinogens Immunotherapy targeted therapy medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer research bladder cancer business |
| Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 11 (2021) |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2021.705294 |
| Popis: | Urothelial carcinoma therapy is a rapidly evolving and expanding field. Traditional cytotoxic chemotherapy regimens have not produced optimal long-term outcomes, and many urothelial cancer patients have comorbidities that disqualify them as chemotherapy candidates. In recent years, a plethora of novel therapeutic agents that target diverse molecular pathways has emerged as alternative treatment modalities for not only metastatic urothelial carcinoma, but also for muscle-invasive bladder cancer and non-muscle invasive bladder cancer in adjuvant and definitive settings. This review paper aims to discuss the various categories of therapeutic agents for these different types of urothelial cancer, discussing immunotherapy, antibody-drug conjugates, kinase inhibitors, CAR-T cell therapy, peptide vaccination, and other drugs targeting pathways such as angiogenesis, DNA synthesis, mTOR/PI3K/AKT, and EGFR/HER-2. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|